1-7 of 7
Keith Stewart, M.D
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.

Craig B. Reeder, MD, Donna E. Reece, M.D., Rafael Fonseca, M.D., P. Leif Bergsagel, M.D., Joseph Hentz, MSc., Nicholas A. Pirooz, BSc., Jacy E. Boesiger, RN., Jesus G. Pisa, M.D., Vishal Kukreti, M.D., Christine Chen, M.D., Suzanne Trudel, M.D., Joseph R. Mikhael, M.D., Martha Lacy, M.D., S. Vincent Rajkumar, M.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2007) 110 (11): 3601.
https://doi.org/10.1182/blood.V110.11.3601.3601
Published: 2007
Journal Articles

Identification of Vacuolar H + - ATPase as a Target for Myeloma Therapeutics.

Yuan Xiao Zhu, PhD, Chung Xin, Shi, Ph.D., Sheng Ben Liang Lian, Ph.D., Wee-Joo Chng, M.D., Suzanne Trudel, M.D., Keith Stewart, M.D.
Journal: Blood
Blood (2007) 110 (11): 257.
https://doi.org/10.1182/blood.V110.11.257.257
Published: 2007
Journal Articles

RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.

Yuan Xiao Zhu, PhD, Holly Yin, Ph.D., Qiang Que, Ph.D., Rodger E. Tiedemann, M.D., Ph.D., Wee-Joo Chng, M.D., Chang Xin Shi, Ph.D., Spyro Mousses, Ph.D, Keith Stewart, M.D
Journal: Blood
Blood (2007) 110 (11): 2478.
https://doi.org/10.1182/blood.V110.11.2478.2478
Published: 2007
Journal Articles

Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.

Donna E. Reece, MD, Young Trieu, M.S., Alida Pokoradi, B.S., Wei Xu, Ph.D., Sharon Fung, M.S., Christine Chen, M.D., Vishal Kukreti, M.D., Joseph Mikhael, M.D., Suzanne Trudel, M.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2007) 110 (11): 950.
https://doi.org/10.1182/blood.V110.11.950.950
Published: 2007
Journal Articles

Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.

Suzanne Trudel, M.D., M.Sc., Ellen Wei, M.Sc., Zhi Hua Li, M.Sc., Eran Rom, Ph.D., Ira Chumakov, M.Sc., Yossi Singer, M.Sc., Chris Chen, M.D., Donna Reece, M.D., Joseph Mikhael, M.D., A. Keith Stewart, M.D., Avner Yayon, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2479.
https://doi.org/10.1182/blood.V104.11.2479.2479
Published: 2004
Journal Articles

CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma.

Suzanne Trudel, M.D., M.Sc., Zhi Hua Li, M.D., Ellen Wei, M.Sc., Marion Wiesmann, Ph.D., Katherine Rendahl, Ph.D., Eddie Moler, Ph.D., Chris Chen, M.D., Donna Reece, M.D., Joesph Mikhael, M.D., Carla Heise, Ph.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2004) 104 (11): 641.
https://doi.org/10.1182/blood.V104.11.641.641
Published: 2004
Journal Articles

Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases.

Jaime O. Claudio, Ph.D., Razi Khaja, B.Sc., Lihua Zhuang, M.D., Meenakshi Bali, B.Sc., Kamalanayani Sivananthan, B.Sc., Constantine C. Christopoulos, B.Sc., Rafael Fonseca, M.D., P. Leif Bergsagel, M.D., Stephen W. Scherer, Ph.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2004) 104 (11): 783.
https://doi.org/10.1182/blood.V104.11.783.783
Published: 2004